Kite Pharma Inc (NASDAQ:KITE) – Equities researchers at Roth Capital reduced their FY2019 EPS estimates for shares of Kite Pharma in a research report issued on Monday, Zacks Investment Research reports. Roth Capital analyst M. Breidenbach now expects that the biopharmaceutical company will post earnings of ($3.40) per share for the year, down from their previous forecast of ($3.27). Roth Capital currently has a “Buy” rating and a $93.00 target price on the stock.

Kite Pharma (NASDAQ:KITE) last released its quarterly earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.75) by $0.05. The firm had revenue of $4.90 million for the quarter, compared to analysts’ expectations of $5.74 million. Kite Pharma had a negative net margin of 994.89% and a negative return on equity of 39.26%. The business’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.54) EPS. TRADEMARK VIOLATION WARNING: “Kite Pharma Inc (KITE) to Post FY2019 Earnings of ($3.40) Per Share, Roth Capital Forecasts” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/04/21/fy2019-eps-estimates-for-kite-pharma-inc-kite-decreased-by-analyst-updated.html.

Earnings History and Estimates for Kite Pharma (NASDAQ:KITE)

A number of other equities analysts have also recently commented on the stock. Royal Bank of Canada boosted their price target on shares of Kite Pharma from $85.00 to $95.00 and gave the stock an “outperform” rating in a research note on Monday, March 6th. Cowen and Company reissued an “outperform” rating on shares of Kite Pharma in a research note on Thursday, April 6th. Zacks Investment Research cut shares of Kite Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 17th. Vetr raised shares of Kite Pharma from a “strong sell” rating to a “sell” rating and set a $67.54 price target for the company in a research note on Monday, March 6th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $72.00 price target on shares of Kite Pharma in a research note on Tuesday, January 24th. Nine equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $80.46.



Kite Pharma (NASDAQ:KITE) traded down 2.03% on Thursday, reaching $79.50. 989,268 shares of the company’s stock traded hands. The company’s 50 day moving average is $79.02 and its 200-day moving average is $57.60. The stock’s market cap is $3.99 billion. Kite Pharma has a 52-week low of $39.82 and a 52-week high of $88.58.

Several hedge funds have recently made changes to their positions in KITE. New York State Common Retirement Fund increased its stake in shares of Kite Pharma by 26.0% in the third quarter. New York State Common Retirement Fund now owns 47,393 shares of the biopharmaceutical company’s stock worth $2,647,000 after buying an additional 9,776 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of Kite Pharma by 5.7% in the third quarter. BlackRock Fund Advisors now owns 1,751,216 shares of the biopharmaceutical company’s stock worth $97,823,000 after buying an additional 94,421 shares during the last quarter. BlackRock Inc. increased its stake in shares of Kite Pharma by 2.2% in the third quarter. BlackRock Inc. now owns 4,112 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 90 shares during the last quarter. BlackRock Investment Management LLC increased its stake in shares of Kite Pharma by 0.7% in the third quarter. BlackRock Investment Management LLC now owns 147,320 shares of the biopharmaceutical company’s stock worth $8,229,000 after buying an additional 1,094 shares during the last quarter. Finally, BlackRock Advisors LLC increased its stake in shares of Kite Pharma by 5.0% in the third quarter. BlackRock Advisors LLC now owns 48,634 shares of the biopharmaceutical company’s stock worth $2,717,000 after buying an additional 2,311 shares during the last quarter. 80.73% of the stock is currently owned by hedge funds and other institutional investors.

In other news, COO Cynthia M. Butitta sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, January 31st. The shares were sold at an average price of $50.56, for a total transaction of $505,600.00. Following the sale, the chief operating officer now owns 127,795 shares of the company’s stock, valued at approximately $6,461,315.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Cynthia M. Butitta sold 38,882 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $73.46, for a total transaction of $2,856,271.72. Following the sale, the chief operating officer now directly owns 127,795 shares in the company, valued at approximately $9,387,820.70. The disclosure for this sale can be found here. Insiders sold a total of 299,876 shares of company stock valued at $22,663,456 over the last 90 days. Company insiders own 20.60% of the company’s stock.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

5 Day Chart for NASDAQ:KITE

Get a free copy of the Zacks research report on Kite Pharma (KITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related stocks with our FREE daily email newsletter.